TransLite LLC

345 Commerce Green Blvd., 77478 Sugar Land, TX
United States of America
Telephone +1 281 2403111
Fax +1 281 2403122
info@veinlite.com
http://www.veinlite.com

Product Categories

01 Electromedical equipment / Medical Technology
01.01 Diagnostics
01.01.01 General Diagnostics
MEDICA 2017
General Diagnostics

Veinlite LED+®
Veinlite PEDI®
Veinlite LEDX®
Veinlite LED Disposable Plastic Covers
4 Products

ad: contact information

Company

Company details
OUR MISSION
To design innovative medical products that help mankind
Produce highest quality products at affordable prices
Provide excellent service and support to our customers
WHO WE ARE
TransLite LLC is a small high tech company comprising dedicated people who design, manufacture and sell medical devices that can help reduce the pain and trauma to patients during venous access and treatment of varicose veins.

IN THE BEGINING
TransLite LLC was started in 1992 to commercialize an innovative product called the Nevoscope for skin cancer detection. The Nevoscope device was designed by Dr. Atam Dhawan and used an innovative technique called side-transillumination for making a small area of the skin translucent. A patent was issued on the Nevoscope design to Dr. Dhawan and was assigned to Mr. Nizar Mullani for commercialization.

A new Nevoscope was designed by Mr. Mullani to incorporate cross-polarized surface imaging of the skin together with side-transillumination for skin cancer detection. This new device was used in a clinical study funded by the NIH to study the use of transillumination for skin cancer detection. The study was carried out at M D Anderson Melanoma Center under the direction of Dr. Duvic. Ms. Claire Terry was hired to oversee the image and data acquisition for this study. Over 250 skin lesions were imaged using the new Nevoscope. Five different modalities of imaging skin cancer were obtained for each lesion including contact and non-contact imaging with cross-polarized imaging and transillumiination.

Preliminary results from this study were presented at the American Academy of Dermatology Annual conference in 1998 by the researchers from M D Anderson Cancer Center. These results showed that cross-polarized imaging was a simple way of imaging superficial structures in the skin lesion while transillumination showed the deeper structures better. Moreover, imaging the skin lesion with contact glass plate reduced the “blush” caused by increased blood volume in a skin lesion. This was observed with both cross-polarized imaging and transillumination imaging. The effect was stronger for transillumination imaging.

CREATION OF THE DERMLITE
Cross polarized imaging of skin lesion was found to be very effective and easy way to image early skin cancer without the use of contact glass plate and oil as was used in the Dermatoscope in those days. In 2000, Mr. Mullani built a prototype of a small white LED based cross-polarized device called the DermLite for imaging skin lesions. This was demonstrated at the Annual Academy of Dermatology meeting in 2000 and a partnership was formed between Mr. Mullani, Mr. John Bottjer and Mr. Thorsten Trotzenberg to commercialize the DermLite for skin cancer detection. The newly formed company was called 3Gen and its first product called the DL 100 was introduced in 2001 at the AAD meeting. Today, over 50% of the dermatologists use DermLite products to screen for skin cancer and non-contact imaging with polarized light has become the main mode of skin cancer imaging for clinical screening.

ad: contact information